home / stock / ettx / ettx news

ETTX News and Press, Entasis Therapeutics Holdings Inc. From 05/16/19

Stock Information
Company Name: Entasis Therapeutics Holdings Inc.
Stock Symbol: ETTX
Market: NASDAQ
Website: entasistx.com
Menu
ETTX ETTX Quote ETTX Short ETTX News ETTX Articles ETTX Message Board
Get ETTX Alerts

News, Short Squeeze, Breakout and More Instantly...
ETTX - Zai Lab on go with China study of antibiotic combo

The China National Medical Products Administration has signed off on Zai Lab's ( ZLAB -4% ) application to conduct a Phase 3 clinical trial there evaluating ETX2514SUL, a fixed-dose combination of a broad spectrum β-lactamase inhibitor with sulbactam, for the treatment of pneumoni...
ETTX - Entasis Therapeutics reports Q1 results

Entasis Therapeutics (NASDAQ: ETTX ): Q1 GAAP EPS of -$0.99. More news on: Entasis Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...

ETTX - Entasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

WALTHAM, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its first quarter financial results ended March 31, 2019 and pro...

ETTX - Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Off...
ETTX - Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer

WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of Eric Kimble as Chief Commercial Offic...

ETTX - Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinica...

ETTX - Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019

WALTHAM, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced multiple data presentations on ETX2514SUL an...
ETTX - Entasis launches late-stage study of antibiotic combo

Entasis Therapeutics ( ETTX ) initiates a Phase 3 clinical trial, ATTACK , evaluating ETX2514SUL, a fixed-dose combination of its broad-spectrum β-lactamase inhibitor ETX2514 with sulbactam, for the treatment of patients with pneumonia and bloodstream infections caused by carbapene...

ETTX - Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections

WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today announced the initiation of the ATTACK ( A cinetobacter T r...

ETTX - Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London

WALTHAM, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Off...
Previous 10 Next 10